CSIMarket Company Name, Ticker, Customers, else..
 

Global Blood Therapeutics Inc.  (NASDAQ: GBT)

Global Blood Therapeutics Inc's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

GBT Sales vs. its Competitors Q2 2022


Comparing the current results to its competitors, Global Blood Therapeutics Inc reported Revenue increase in the 2 quarter 2022 by 50.46 % year on year.
The revenue growth was below Global Blood Therapeutics Inc's competitors' average revenue growth of 63.29 %, achieved in the same quarter.

• List of GBT Competitors





Revenue Growth Comparisons




Net Income Comparison

Global Blood Therapeutics Inc. recorded a net loss, as well as most of its competitors.

<<  GBT Stock Performance Comparisons





  

Overall company Market Share Q2 2022
Contrary to strong revenue growth of 50.46 % in Overall company, Global Blood Therapeutics Inc lost market share within this segment.




<<  More on GBT Market Share.
 
*Market share is calculated based on total revenue.





Publicly Traded Peers of Global Blood Therapeutics Inc.




Chemomab Therapeutics Ltd
Share Performance



+54.19%
This Year
Chemomab Therapeutics Ltd
Profile

Chemomab Therapeutics Ltd is a biotechnology company focused on developing innovative treatments for fibrosis-related diseases. Their business model revolves around the research and development of therapeutic antibodies targeting specific pathways involved in fibrosis. By leveraging their scientific expertise and strategic collaborations, the company aims to ultimately bring effective and safe therapies to market, addressing the unmet medical needs of patients suffering from fibrosis.

More about Chemomab Therapeutics Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,408.228 mill. $ - mill. $ 8.995 mill.


Editas Medicine Inc
Share Performance



+9.57%
30 Days
Editas Medicine Inc
Profile

Editas Medicine Inc.'s business model revolves around developing and commercializing transformative genome editing technologies to treat serious diseases.

More about Editas Medicine Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 297.064 mill. $ 38.693 mill. $ -108.954 mill.


Contextlogic Inc
Share Performance



+30.63%
30 Days
Contextlogic Inc
Profile

LogicBio Therapeutics Inc is a biotechnology company that focuses on developing and commercializing gene editing technology to treat rare genetic diseases.

More about Contextlogic Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 337.908 mill. $ - mill. $ 120.000 mill.


Sigilon Therapeutics Inc
Share Performance



+3.98%
Over The Past 5 Days
Sigilon Therapeutics Inc
Profile

Sigilon Therapeutics Inc is a biotechnology company that focuses on developing novel therapies using advanced cell engineering and implantable devices to treat chronic diseases.

More about Sigilon Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 56.218 mill. $ 17.654 mill. $ -30.240 mill.

Sources: Global Blood Therapeutics Inc.’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Global Blood Therapeutics Inc. versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.